nodes	percent_of_prediction	percent_of_DWPC	metapath
Alitretinoin—ABCB1—Lisinopril—dilated cardiomyopathy	0.126	0.532	CbGbCtD
Alitretinoin—ABCB1—Spironolactone—dilated cardiomyopathy	0.111	0.468	CbGbCtD
Alitretinoin—CRABP1—Pyruvate metabolism and Citric Acid (TCA) cycle—SDHA—dilated cardiomyopathy	0.0164	0.0523	CbGpPWpGaD
Alitretinoin—CRABP2—Pyruvate metabolism and Citric Acid (TCA) cycle—SDHA—dilated cardiomyopathy	0.0164	0.0523	CbGpPWpGaD
Alitretinoin—RXRG—a6b1 and a6b4 Integrin signaling—LAMA4—dilated cardiomyopathy	0.00972	0.031	CbGpPWpGaD
Alitretinoin—RXRB—a6b1 and a6b4 Integrin signaling—LAMA4—dilated cardiomyopathy	0.00914	0.0291	CbGpPWpGaD
Alitretinoin—RARG—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.00818	0.026	CbGpPWpGaD
Alitretinoin—RXRG—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.00748	0.0238	CbGpPWpGaD
Alitretinoin—RARB—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.00733	0.0234	CbGpPWpGaD
Alitretinoin—RARA—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.00703	0.0224	CbGpPWpGaD
Alitretinoin—RXRB—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.00703	0.0224	CbGpPWpGaD
Alitretinoin—CRABP1—Fatty acid, triacylglycerol, and ketone body metabolism—ANKRD1—dilated cardiomyopathy	0.00637	0.0203	CbGpPWpGaD
Alitretinoin—CRABP2—Fatty acid, triacylglycerol, and ketone body metabolism—ANKRD1—dilated cardiomyopathy	0.00637	0.0203	CbGpPWpGaD
Alitretinoin—CRABP1—The citric acid (TCA) cycle and respiratory electron transport—SDHA—dilated cardiomyopathy	0.00637	0.0203	CbGpPWpGaD
Alitretinoin—CRABP2—The citric acid (TCA) cycle and respiratory electron transport—SDHA—dilated cardiomyopathy	0.00637	0.0203	CbGpPWpGaD
Alitretinoin—Vasculitis—Spironolactone—dilated cardiomyopathy	0.00498	0.0111	CcSEcCtD
Alitretinoin—RXRA—Pyruvate metabolism and Citric Acid (TCA) cycle—SDHA—dilated cardiomyopathy	0.00497	0.0158	CbGpPWpGaD
Alitretinoin—Flank pain—Lisinopril—dilated cardiomyopathy	0.00492	0.011	CcSEcCtD
Alitretinoin—Local reaction—Furosemide—dilated cardiomyopathy	0.00477	0.0106	CcSEcCtD
Alitretinoin—RXRA—a6b1 and a6b4 Integrin signaling—LAMA4—dilated cardiomyopathy	0.00476	0.0152	CbGpPWpGaD
Alitretinoin—RARG—RXR and RAR heterodimerization with other nuclear receptor—RPS6KB1—dilated cardiomyopathy	0.00474	0.0151	CbGpPWpGaD
Alitretinoin—CRABP2—Vitamin A and Carotenoid Metabolism—CD36—dilated cardiomyopathy	0.0045	0.0143	CbGpPWpGaD
Alitretinoin—CRABP1—Vitamin A and Carotenoid Metabolism—CD36—dilated cardiomyopathy	0.0045	0.0143	CbGpPWpGaD
Alitretinoin—RXRG—RXR and RAR heterodimerization with other nuclear receptor—RPS6KB1—dilated cardiomyopathy	0.00434	0.0138	CbGpPWpGaD
Alitretinoin—RARB—RXR and RAR heterodimerization with other nuclear receptor—RPS6KB1—dilated cardiomyopathy	0.00426	0.0136	CbGpPWpGaD
Alitretinoin—Lung infiltration—Lisinopril—dilated cardiomyopathy	0.00423	0.00943	CcSEcCtD
Alitretinoin—RARA—RXR and RAR heterodimerization with other nuclear receptor—RPS6KB1—dilated cardiomyopathy	0.00408	0.013	CbGpPWpGaD
Alitretinoin—RXRB—RXR and RAR heterodimerization with other nuclear receptor—RPS6KB1—dilated cardiomyopathy	0.00408	0.013	CbGpPWpGaD
Alitretinoin—Blood triglycerides increased—Furosemide—dilated cardiomyopathy	0.00403	0.00899	CcSEcCtD
Alitretinoin—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.00382	0.00852	CcSEcCtD
Alitretinoin—Thrombosis—Furosemide—dilated cardiomyopathy	0.00373	0.00833	CcSEcCtD
Alitretinoin—Ear disorder—Lisinopril—dilated cardiomyopathy	0.00367	0.00819	CcSEcCtD
Alitretinoin—Blister—Furosemide—dilated cardiomyopathy	0.00367	0.00818	CcSEcCtD
Alitretinoin—RXRA—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.00366	0.0117	CbGpPWpGaD
Alitretinoin—RXRA—YAP1- and WWTR1 (TAZ)-stimulated gene expression—NPPA—dilated cardiomyopathy	0.00361	0.0115	CbGpPWpGaD
Alitretinoin—Lethargy—Spironolactone—dilated cardiomyopathy	0.0036	0.00802	CcSEcCtD
Alitretinoin—Blindness—Lisinopril—dilated cardiomyopathy	0.00358	0.00799	CcSEcCtD
Alitretinoin—Serum creatinine increased—Lisinopril—dilated cardiomyopathy	0.00322	0.00719	CcSEcCtD
Alitretinoin—Fluid overload—Lisinopril—dilated cardiomyopathy	0.00319	0.00711	CcSEcCtD
Alitretinoin—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00318	0.00708	CcSEcCtD
Alitretinoin—RXRG—a6b1 and a6b4 Integrin signaling—ITGB1—dilated cardiomyopathy	0.00314	0.01	CbGpPWpGaD
Alitretinoin—Gastritis—Spironolactone—dilated cardiomyopathy	0.00312	0.00696	CcSEcCtD
Alitretinoin—Laryngeal oedema—Lisinopril—dilated cardiomyopathy	0.00309	0.00689	CcSEcCtD
Alitretinoin—RARG—Vitamin A and Carotenoid Metabolism—CD36—dilated cardiomyopathy	0.00304	0.00968	CbGpPWpGaD
Alitretinoin—RXRB—a6b1 and a6b4 Integrin signaling—ITGB1—dilated cardiomyopathy	0.00296	0.00941	CbGpPWpGaD
Alitretinoin—RXRA—PPARA activates gene expression—ANKRD1—dilated cardiomyopathy	0.00286	0.0091	CbGpPWpGaD
Alitretinoin—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.00285	0.00635	CcSEcCtD
Alitretinoin—Drug interaction—Furosemide—dilated cardiomyopathy	0.00285	0.00635	CcSEcCtD
Alitretinoin—Gout—Furosemide—dilated cardiomyopathy	0.00283	0.00631	CcSEcCtD
Alitretinoin—RXRG—a6b1 and a6b4 Integrin signaling—RPS6KB1—dilated cardiomyopathy	0.0028	0.00891	CbGpPWpGaD
Alitretinoin—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ANKRD1—dilated cardiomyopathy	0.0028	0.00891	CbGpPWpGaD
Alitretinoin—RXRG—Vitamin A and Carotenoid Metabolism—CD36—dilated cardiomyopathy	0.00278	0.00886	CbGpPWpGaD
Alitretinoin—Hearing impaired—Furosemide—dilated cardiomyopathy	0.00278	0.00619	CcSEcCtD
Alitretinoin—Hyperlipidaemia—Lisinopril—dilated cardiomyopathy	0.00275	0.00613	CcSEcCtD
Alitretinoin—RARB—Vitamin A and Carotenoid Metabolism—CD36—dilated cardiomyopathy	0.00273	0.00869	CbGpPWpGaD
Alitretinoin—Drowsiness—Spironolactone—dilated cardiomyopathy	0.00272	0.00606	CcSEcCtD
Alitretinoin—Vasculitis—Furosemide—dilated cardiomyopathy	0.00271	0.00604	CcSEcCtD
Alitretinoin—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00269	0.00601	CcSEcCtD
Alitretinoin—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.00269	0.006	CcSEcCtD
Alitretinoin—Renal failure—Spironolactone—dilated cardiomyopathy	0.00267	0.00596	CcSEcCtD
Alitretinoin—RXRB—a6b1 and a6b4 Integrin signaling—RPS6KB1—dilated cardiomyopathy	0.00263	0.00838	CbGpPWpGaD
Alitretinoin—RXRB—Vitamin A and Carotenoid Metabolism—CD36—dilated cardiomyopathy	0.00262	0.00833	CbGpPWpGaD
Alitretinoin—RARA—Vitamin A and Carotenoid Metabolism—CD36—dilated cardiomyopathy	0.00262	0.00833	CbGpPWpGaD
Alitretinoin—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.00259	0.00577	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00255	0.00812	CbGpPWpGaD
Alitretinoin—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00254	0.00565	CcSEcCtD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00254	0.00807	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00254	0.00807	CbGpPWpGaD
Alitretinoin—RXRG—a6b1 and a6b4 Integrin signaling—RAC1—dilated cardiomyopathy	0.00253	0.00805	CbGpPWpGaD
Alitretinoin—Memory impairment—Lisinopril—dilated cardiomyopathy	0.00253	0.00563	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00244	0.00778	CbGpPWpGaD
Alitretinoin—Bladder pain—Furosemide—dilated cardiomyopathy	0.00239	0.00533	CcSEcCtD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.00238	0.00759	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.00238	0.00759	CbGpPWpGaD
Alitretinoin—RXRB—a6b1 and a6b4 Integrin signaling—RAC1—dilated cardiomyopathy	0.00238	0.00757	CbGpPWpGaD
Alitretinoin—Lightheadedness—Furosemide—dilated cardiomyopathy	0.00236	0.00527	CcSEcCtD
Alitretinoin—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00231	0.00514	CcSEcCtD
Alitretinoin—Proteinuria—Lisinopril—dilated cardiomyopathy	0.00226	0.00503	CcSEcCtD
Alitretinoin—Chest discomfort—Lisinopril—dilated cardiomyopathy	0.00224	0.005	CcSEcCtD
Alitretinoin—Protein urine present—Lisinopril—dilated cardiomyopathy	0.00223	0.00496	CcSEcCtD
Alitretinoin—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00221	0.00492	CcSEcCtD
Alitretinoin—Photosensitivity—Furosemide—dilated cardiomyopathy	0.00218	0.00487	CcSEcCtD
Alitretinoin—Swelling—Furosemide—dilated cardiomyopathy	0.00217	0.00485	CcSEcCtD
Alitretinoin—Alopecia—Spironolactone—dilated cardiomyopathy	0.00216	0.00481	CcSEcCtD
Alitretinoin—Deafness—Furosemide—dilated cardiomyopathy	0.00214	0.00478	CcSEcCtD
Alitretinoin—Drug interaction—Lisinopril—dilated cardiomyopathy	0.00214	0.00477	CcSEcCtD
Alitretinoin—RXRA—RXR and RAR heterodimerization with other nuclear receptor—RPS6KB1—dilated cardiomyopathy	0.00213	0.00677	CbGpPWpGaD
Alitretinoin—Gout—Lisinopril—dilated cardiomyopathy	0.00212	0.00474	CcSEcCtD
Alitretinoin—Leukocytosis—Lisinopril—dilated cardiomyopathy	0.00211	0.0047	CcSEcCtD
Alitretinoin—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00203	0.00453	CcSEcCtD
Alitretinoin—Vasculitis—Lisinopril—dilated cardiomyopathy	0.00203	0.00453	CcSEcCtD
Alitretinoin—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00201	0.00448	CcSEcCtD
Alitretinoin—Neck pain—Lisinopril—dilated cardiomyopathy	0.00201	0.00448	CcSEcCtD
Alitretinoin—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00201	0.00448	CcSEcCtD
Alitretinoin—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00197	0.00439	CcSEcCtD
Alitretinoin—Lethargy—Furosemide—dilated cardiomyopathy	0.00196	0.00437	CcSEcCtD
Alitretinoin—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00194	0.00432	CcSEcCtD
Alitretinoin—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—ANKRD1—dilated cardiomyopathy	0.00193	0.00614	CbGpPWpGaD
Alitretinoin—RXRA—The citric acid (TCA) cycle and respiratory electron transport—SDHA—dilated cardiomyopathy	0.00193	0.00614	CbGpPWpGaD
Alitretinoin—Wheezing—Lisinopril—dilated cardiomyopathy	0.00193	0.00429	CcSEcCtD
Alitretinoin—Malaise—Spironolactone—dilated cardiomyopathy	0.00191	0.00427	CcSEcCtD
Alitretinoin—Cystitis—Lisinopril—dilated cardiomyopathy	0.00191	0.00427	CcSEcCtD
Alitretinoin—RXRG—Adipogenesis—LMNA—dilated cardiomyopathy	0.00189	0.00601	CbGpPWpGaD
Alitretinoin—Photophobia—Lisinopril—dilated cardiomyopathy	0.00186	0.00415	CcSEcCtD
Alitretinoin—RARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—dilated cardiomyopathy	0.00186	0.00591	CbGpPWpGaD
Alitretinoin—Irritability—Furosemide—dilated cardiomyopathy	0.00183	0.00408	CcSEcCtD
Alitretinoin—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.0018	0.00573	CbGpPWpGaD
Alitretinoin—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.0018	0.00401	CcSEcCtD
Alitretinoin—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00179	0.004	CcSEcCtD
Alitretinoin—Discomfort—Spironolactone—dilated cardiomyopathy	0.00179	0.00398	CcSEcCtD
Alitretinoin—Dehydration—Furosemide—dilated cardiomyopathy	0.00178	0.00398	CcSEcCtD
Alitretinoin—RARA—Adipogenesis—LMNA—dilated cardiomyopathy	0.00178	0.00565	CbGpPWpGaD
Alitretinoin—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.00177	0.00396	CcSEcCtD
Alitretinoin—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.00176	0.00394	CcSEcCtD
Alitretinoin—Confusional state—Spironolactone—dilated cardiomyopathy	0.00175	0.0039	CcSEcCtD
Alitretinoin—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00173	0.00386	CcSEcCtD
Alitretinoin—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00173	0.00385	CcSEcCtD
Alitretinoin—RXRG—RXR and RAR heterodimerization with other nuclear receptor—TNF—dilated cardiomyopathy	0.0017	0.00541	CbGpPWpGaD
Alitretinoin—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.0017	0.00378	CcSEcCtD
Alitretinoin—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00167	0.00372	CcSEcCtD
Alitretinoin—RARB—RXR and RAR heterodimerization with other nuclear receptor—TNF—dilated cardiomyopathy	0.00166	0.0053	CbGpPWpGaD
Alitretinoin—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00165	0.00369	CcSEcCtD
Alitretinoin—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.00164	0.00366	CcSEcCtD
Alitretinoin—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00163	0.00362	CcSEcCtD
Alitretinoin—Eczema—Lisinopril—dilated cardiomyopathy	0.0016	0.00357	CcSEcCtD
Alitretinoin—RARA—RXR and RAR heterodimerization with other nuclear receptor—TNF—dilated cardiomyopathy	0.0016	0.00508	CbGpPWpGaD
Alitretinoin—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TNF—dilated cardiomyopathy	0.0016	0.00508	CbGpPWpGaD
Alitretinoin—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.00158	0.00352	CcSEcCtD
Alitretinoin—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00156	0.00348	CcSEcCtD
Alitretinoin—RXRA—a6b1 and a6b4 Integrin signaling—ITGB1—dilated cardiomyopathy	0.00154	0.00491	CbGpPWpGaD
Alitretinoin—Somnolence—Spironolactone—dilated cardiomyopathy	0.00154	0.00344	CcSEcCtD
Alitretinoin—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00153	0.00342	CcSEcCtD
Alitretinoin—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00151	0.00337	CcSEcCtD
Alitretinoin—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00151	0.00337	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.0015	0.00334	CcSEcCtD
Alitretinoin—Arthritis—Lisinopril—dilated cardiomyopathy	0.00148	0.0033	CcSEcCtD
Alitretinoin—Drowsiness—Furosemide—dilated cardiomyopathy	0.00148	0.0033	CcSEcCtD
Alitretinoin—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00147	0.00328	CcSEcCtD
Alitretinoin—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00147	0.00327	CcSEcCtD
Alitretinoin—Renal failure—Furosemide—dilated cardiomyopathy	0.00145	0.00324	CcSEcCtD
Alitretinoin—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00144	0.00321	CcSEcCtD
Alitretinoin—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00144	0.00321	CcSEcCtD
Alitretinoin—CRABP2—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	0.00143	0.00456	CbGpPWpGaD
Alitretinoin—CRABP1—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	0.00143	0.00456	CbGpPWpGaD
Alitretinoin—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00143	0.00318	CcSEcCtD
Alitretinoin—Sweating—Furosemide—dilated cardiomyopathy	0.00142	0.00316	CcSEcCtD
Alitretinoin—RARG—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	0.00141	0.0045	CbGpPWpGaD
Alitretinoin—Face oedema—Lisinopril—dilated cardiomyopathy	0.00139	0.0031	CcSEcCtD
Alitretinoin—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00138	0.00308	CcSEcCtD
Alitretinoin—Urticaria—Spironolactone—dilated cardiomyopathy	0.00138	0.00307	CcSEcCtD
Alitretinoin—Irritability—Lisinopril—dilated cardiomyopathy	0.00137	0.00306	CcSEcCtD
Alitretinoin—RXRA—a6b1 and a6b4 Integrin signaling—RPS6KB1—dilated cardiomyopathy	0.00137	0.00437	CbGpPWpGaD
Alitretinoin—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00137	0.00306	CcSEcCtD
Alitretinoin—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.00137	0.00305	CcSEcCtD
Alitretinoin—RXRA—Vitamin A and Carotenoid Metabolism—CD36—dilated cardiomyopathy	0.00136	0.00434	CbGpPWpGaD
Alitretinoin—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00135	0.00301	CcSEcCtD
Alitretinoin—Dehydration—Lisinopril—dilated cardiomyopathy	0.00134	0.00298	CcSEcCtD
Alitretinoin—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00131	0.00292	CcSEcCtD
Alitretinoin—Urethral disorder—Furosemide—dilated cardiomyopathy	0.0013	0.0029	CcSEcCtD
Alitretinoin—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.0013	0.00289	CcSEcCtD
Alitretinoin—RXRG—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	0.00129	0.00411	CbGpPWpGaD
Alitretinoin—CRABP2—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	0.00129	0.00411	CbGpPWpGaD
Alitretinoin—CRABP1—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	0.00129	0.00411	CbGpPWpGaD
Alitretinoin—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00129	0.00287	CcSEcCtD
Alitretinoin—Visual impairment—Furosemide—dilated cardiomyopathy	0.00128	0.00285	CcSEcCtD
Alitretinoin—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00128	0.00285	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00127	0.00406	CbGpPWpGaD
Alitretinoin—Gastritis—Lisinopril—dilated cardiomyopathy	0.00127	0.00284	CcSEcCtD
Alitretinoin—RARB—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	0.00127	0.00403	CbGpPWpGaD
Alitretinoin—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00125	0.0028	CcSEcCtD
Alitretinoin—Asthma—Lisinopril—dilated cardiomyopathy	0.00124	0.00277	CcSEcCtD
Alitretinoin—Eye disorder—Furosemide—dilated cardiomyopathy	0.00124	0.00277	CcSEcCtD
Alitretinoin—RXRA—a6b1 and a6b4 Integrin signaling—RAC1—dilated cardiomyopathy	0.00124	0.00394	CbGpPWpGaD
Alitretinoin—Tinnitus—Furosemide—dilated cardiomyopathy	0.00124	0.00276	CcSEcCtD
Alitretinoin—Pruritus—Spironolactone—dilated cardiomyopathy	0.00123	0.00273	CcSEcCtD
Alitretinoin—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.00122	0.00273	CcSEcCtD
Alitretinoin—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00122	0.00272	CcSEcCtD
Alitretinoin—RXRB—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	0.00121	0.00387	CbGpPWpGaD
Alitretinoin—RARA—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	0.00121	0.00387	CbGpPWpGaD
Alitretinoin—Sweating increased—Lisinopril—dilated cardiomyopathy	0.00121	0.0027	CcSEcCtD
Alitretinoin—Angiopathy—Furosemide—dilated cardiomyopathy	0.0012	0.00269	CcSEcCtD
Alitretinoin—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00119	0.00264	CcSEcCtD
Alitretinoin—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00119	0.00264	CcSEcCtD
Alitretinoin—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00116	0.00259	CcSEcCtD
Alitretinoin—Dysuria—Lisinopril—dilated cardiomyopathy	0.00116	0.00259	CcSEcCtD
Alitretinoin—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00116	0.00258	CcSEcCtD
Alitretinoin—Erythema—Furosemide—dilated cardiomyopathy	0.00116	0.00258	CcSEcCtD
Alitretinoin—Malnutrition—Furosemide—dilated cardiomyopathy	0.00116	0.00258	CcSEcCtD
Alitretinoin—RXRG—a6b1 and a6b4 Integrin signaling—EGFR—dilated cardiomyopathy	0.00115	0.00366	CbGpPWpGaD
Alitretinoin—Dizziness—Spironolactone—dilated cardiomyopathy	0.00115	0.00256	CcSEcCtD
Alitretinoin—Flatulence—Furosemide—dilated cardiomyopathy	0.00114	0.00254	CcSEcCtD
Alitretinoin—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00114	0.00253	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—ZIC3—dilated cardiomyopathy	0.00113	0.00361	CbGpPWpGaD
Alitretinoin—Weight increased—Lisinopril—dilated cardiomyopathy	0.00113	0.00252	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—ANKRD1—dilated cardiomyopathy	0.00113	0.0036	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—ANKRD1—dilated cardiomyopathy	0.00113	0.0036	CbGpPWpGaD
Alitretinoin—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00113	0.00251	CcSEcCtD
Alitretinoin—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00112	0.00249	CcSEcCtD
Alitretinoin—Depression—Lisinopril—dilated cardiomyopathy	0.00111	0.00247	CcSEcCtD
Alitretinoin—RXRG—Adipogenesis—FAS—dilated cardiomyopathy	0.0011	0.00351	CbGpPWpGaD
Alitretinoin—Vomiting—Spironolactone—dilated cardiomyopathy	0.0011	0.00246	CcSEcCtD
Alitretinoin—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.0011	0.00245	CcSEcCtD
Alitretinoin—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00109	0.00244	CcSEcCtD
Alitretinoin—Rash—Spironolactone—dilated cardiomyopathy	0.00109	0.00244	CcSEcCtD
Alitretinoin—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00109	0.00243	CcSEcCtD
Alitretinoin—Renal failure—Lisinopril—dilated cardiomyopathy	0.00109	0.00243	CcSEcCtD
Alitretinoin—Vision blurred—Furosemide—dilated cardiomyopathy	0.00109	0.00243	CcSEcCtD
Alitretinoin—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00109	0.00242	CcSEcCtD
Alitretinoin—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00109	0.00242	CcSEcCtD
Alitretinoin—Headache—Spironolactone—dilated cardiomyopathy	0.00109	0.00242	CcSEcCtD
Alitretinoin—RXRB—a6b1 and a6b4 Integrin signaling—EGFR—dilated cardiomyopathy	0.00108	0.00344	CbGpPWpGaD
Alitretinoin—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00108	0.0024	CcSEcCtD
Alitretinoin—Anaemia—Furosemide—dilated cardiomyopathy	0.00107	0.00238	CcSEcCtD
Alitretinoin—Sweating—Lisinopril—dilated cardiomyopathy	0.00106	0.00237	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—TAZ—dilated cardiomyopathy	0.00106	0.00338	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—TAZ—dilated cardiomyopathy	0.00106	0.00338	CbGpPWpGaD
Alitretinoin—Agitation—Furosemide—dilated cardiomyopathy	0.00106	0.00237	CcSEcCtD
Alitretinoin—Haematuria—Lisinopril—dilated cardiomyopathy	0.00106	0.00236	CcSEcCtD
Alitretinoin—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00105	0.00233	CcSEcCtD
Alitretinoin—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00104	0.00232	CcSEcCtD
Alitretinoin—RARA—Adipogenesis—FAS—dilated cardiomyopathy	0.00104	0.0033	CbGpPWpGaD
Alitretinoin—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00104	0.00231	CcSEcCtD
Alitretinoin—RXRG—Adipogenesis—AGT—dilated cardiomyopathy	0.00103	0.00329	CbGpPWpGaD
Alitretinoin—Nausea—Spironolactone—dilated cardiomyopathy	0.00103	0.0023	CcSEcCtD
Alitretinoin—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000996	0.00222	CcSEcCtD
Alitretinoin—Hallucination—Lisinopril—dilated cardiomyopathy	0.000991	0.00221	CcSEcCtD
Alitretinoin—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000988	0.0022	CcSEcCtD
Alitretinoin—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000983	0.00219	CcSEcCtD
Alitretinoin—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000981	0.00219	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000977	0.00218	CcSEcCtD
Alitretinoin—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000976	0.00218	CcSEcCtD
Alitretinoin—RARA—Adipogenesis—AGT—dilated cardiomyopathy	0.000972	0.00309	CbGpPWpGaD
Alitretinoin—Dry mouth—Furosemide—dilated cardiomyopathy	0.000962	0.00215	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—SDHA—dilated cardiomyopathy	0.00096	0.00306	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—SDHA—dilated cardiomyopathy	0.00096	0.00306	CbGpPWpGaD
Alitretinoin—RXRA—Transcription factor regulation in adipogenesis—TNF—dilated cardiomyopathy	0.000951	0.00303	CbGpPWpGaD
Alitretinoin—Confusional state—Furosemide—dilated cardiomyopathy	0.000951	0.00212	CcSEcCtD
Alitretinoin—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000943	0.0021	CcSEcCtD
Alitretinoin—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000942	0.0021	CcSEcCtD
Alitretinoin—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000928	0.00207	CcSEcCtD
Alitretinoin—Shock—Furosemide—dilated cardiomyopathy	0.000928	0.00207	CcSEcCtD
Alitretinoin—RXRA—Adipogenesis—LMNA—dilated cardiomyopathy	0.000926	0.00295	CbGpPWpGaD
Alitretinoin—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000925	0.00206	CcSEcCtD
Alitretinoin—Flushing—Lisinopril—dilated cardiomyopathy	0.000924	0.00206	CcSEcCtD
Alitretinoin—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000923	0.00206	CcSEcCtD
Alitretinoin—Skin disorder—Furosemide—dilated cardiomyopathy	0.000916	0.00204	CcSEcCtD
Alitretinoin—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000912	0.00203	CcSEcCtD
Alitretinoin—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000903	0.00201	CcSEcCtD
Alitretinoin—Anorexia—Furosemide—dilated cardiomyopathy	0.000899	0.002	CcSEcCtD
Alitretinoin—Chills—Lisinopril—dilated cardiomyopathy	0.000893	0.00199	CcSEcCtD
Alitretinoin—CYP1A2—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.000893	0.00284	CbGpPWpGaD
Alitretinoin—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00089	0.00198	CcSEcCtD
Alitretinoin—RARG—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	0.000887	0.00282	CbGpPWpGaD
Alitretinoin—Hypotension—Furosemide—dilated cardiomyopathy	0.000881	0.00196	CcSEcCtD
Alitretinoin—Alopecia—Lisinopril—dilated cardiomyopathy	0.00088	0.00196	CcSEcCtD
Alitretinoin—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000872	0.00195	CcSEcCtD
Alitretinoin—Erythema—Lisinopril—dilated cardiomyopathy	0.000867	0.00193	CcSEcCtD
Alitretinoin—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000867	0.00193	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—SCN5A—dilated cardiomyopathy	0.000859	0.00274	CbGpPWpGaD
Alitretinoin—RXRA—Transcriptional regulation of white adipocyte differentiation—CD36—dilated cardiomyopathy	0.000855	0.00272	CbGpPWpGaD
Alitretinoin—Flatulence—Lisinopril—dilated cardiomyopathy	0.000854	0.0019	CcSEcCtD
Alitretinoin—Tension—Lisinopril—dilated cardiomyopathy	0.000851	0.0019	CcSEcCtD
Alitretinoin—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000847	0.00189	CcSEcCtD
Alitretinoin—Nervousness—Lisinopril—dilated cardiomyopathy	0.000842	0.00188	CcSEcCtD
Alitretinoin—Back pain—Lisinopril—dilated cardiomyopathy	0.000838	0.00187	CcSEcCtD
Alitretinoin—Somnolence—Furosemide—dilated cardiomyopathy	0.000838	0.00187	CcSEcCtD
Alitretinoin—RXRA—RXR and RAR heterodimerization with other nuclear receptor—TNF—dilated cardiomyopathy	0.000832	0.00265	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000825	0.00263	CbGpPWpGaD
Alitretinoin—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00082	0.00183	CcSEcCtD
Alitretinoin—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000817	0.00182	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000814	0.00182	CcSEcCtD
Alitretinoin—Fatigue—Furosemide—dilated cardiomyopathy	0.000813	0.00181	CcSEcCtD
Alitretinoin—Tremor—Lisinopril—dilated cardiomyopathy	0.000812	0.00181	CcSEcCtD
Alitretinoin—RXRG—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	0.000811	0.00258	CbGpPWpGaD
Alitretinoin—Constipation—Furosemide—dilated cardiomyopathy	0.000806	0.0018	CcSEcCtD
Alitretinoin—Pain—Furosemide—dilated cardiomyopathy	0.000806	0.0018	CcSEcCtD
Alitretinoin—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.000804	0.00179	CcSEcCtD
Alitretinoin—Anaemia—Lisinopril—dilated cardiomyopathy	0.000801	0.00179	CcSEcCtD
Alitretinoin—RARB—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	0.000795	0.00253	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000795	0.00253	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000791	0.00252	CbGpPWpGaD
Alitretinoin—Malaise—Lisinopril—dilated cardiomyopathy	0.000782	0.00174	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.00078	0.00248	CbGpPWpGaD
Alitretinoin—Syncope—Lisinopril—dilated cardiomyopathy	0.000777	0.00173	CcSEcCtD
Alitretinoin—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000777	0.00173	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000771	0.00172	CcSEcCtD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000768	0.00244	CbGpPWpGaD
Alitretinoin—Palpitations—Lisinopril—dilated cardiomyopathy	0.000766	0.00171	CcSEcCtD
Alitretinoin—RXRB—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	0.000763	0.00243	CbGpPWpGaD
Alitretinoin—RARA—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	0.000763	0.00243	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000763	0.00243	CbGpPWpGaD
Alitretinoin—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000762	0.0017	CcSEcCtD
Alitretinoin—Cough—Lisinopril—dilated cardiomyopathy	0.000756	0.00169	CcSEcCtD
Alitretinoin—Urticaria—Furosemide—dilated cardiomyopathy	0.000749	0.00167	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000748	0.00238	CbGpPWpGaD
Alitretinoin—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000745	0.00166	CcSEcCtD
Alitretinoin—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000745	0.00166	CcSEcCtD
Alitretinoin—Myalgia—Lisinopril—dilated cardiomyopathy	0.000738	0.00165	CcSEcCtD
Alitretinoin—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000738	0.00165	CcSEcCtD
Alitretinoin—Chest pain—Lisinopril—dilated cardiomyopathy	0.000738	0.00165	CcSEcCtD
Alitretinoin—Anxiety—Lisinopril—dilated cardiomyopathy	0.000735	0.00164	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000733	0.00163	CcSEcCtD
Alitretinoin—Discomfort—Lisinopril—dilated cardiomyopathy	0.000729	0.00163	CcSEcCtD
Alitretinoin—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000722	0.00161	CcSEcCtD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000722	0.0023	CbGpPWpGaD
Alitretinoin—Confusional state—Lisinopril—dilated cardiomyopathy	0.000713	0.00159	CcSEcCtD
Alitretinoin—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000707	0.00158	CcSEcCtD
Alitretinoin—Oedema—Lisinopril—dilated cardiomyopathy	0.000707	0.00158	CcSEcCtD
Alitretinoin—Infection—Lisinopril—dilated cardiomyopathy	0.000703	0.00157	CcSEcCtD
Alitretinoin—Shock—Lisinopril—dilated cardiomyopathy	0.000696	0.00155	CcSEcCtD
Alitretinoin—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000695	0.00155	CcSEcCtD
Alitretinoin—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000693	0.00154	CcSEcCtD
Alitretinoin—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00069	0.00154	CcSEcCtD
Alitretinoin—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000687	0.00153	CcSEcCtD
Alitretinoin—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000684	0.00153	CcSEcCtD
Alitretinoin—RARG—Gene Expression—NR3C2—dilated cardiomyopathy	0.00068	0.00217	CbGpPWpGaD
Alitretinoin—Asthenia—Furosemide—dilated cardiomyopathy	0.000676	0.00151	CcSEcCtD
Alitretinoin—Anorexia—Lisinopril—dilated cardiomyopathy	0.000674	0.0015	CcSEcCtD
Alitretinoin—Pruritus—Furosemide—dilated cardiomyopathy	0.000667	0.00149	CcSEcCtD
Alitretinoin—Hypotension—Lisinopril—dilated cardiomyopathy	0.000661	0.00147	CcSEcCtD
Alitretinoin—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000645	0.00144	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000645	0.00144	CcSEcCtD
Alitretinoin—RXRA—PPARA activates gene expression—CD36—dilated cardiomyopathy	0.000643	0.00205	CbGpPWpGaD
Alitretinoin—Insomnia—Lisinopril—dilated cardiomyopathy	0.00064	0.00143	CcSEcCtD
Alitretinoin—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000635	0.00142	CcSEcCtD
Alitretinoin—RXRA—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	0.000633	0.00202	CbGpPWpGaD
Alitretinoin—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000631	0.00141	CcSEcCtD
Alitretinoin—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CD36—dilated cardiomyopathy	0.000629	0.002	CbGpPWpGaD
Alitretinoin—Somnolence—Lisinopril—dilated cardiomyopathy	0.000629	0.0014	CcSEcCtD
Alitretinoin—Dizziness—Furosemide—dilated cardiomyopathy	0.000624	0.00139	CcSEcCtD
Alitretinoin—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000623	0.00139	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—NR3C2—dilated cardiomyopathy	0.000622	0.00198	CbGpPWpGaD
Alitretinoin—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000615	0.00137	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000611	0.00136	CcSEcCtD
Alitretinoin—Fatigue—Lisinopril—dilated cardiomyopathy	0.00061	0.00136	CcSEcCtD
Alitretinoin—RARB—Gene Expression—NR3C2—dilated cardiomyopathy	0.00061	0.00194	CbGpPWpGaD
Alitretinoin—Pain—Lisinopril—dilated cardiomyopathy	0.000605	0.00135	CcSEcCtD
Alitretinoin—Constipation—Lisinopril—dilated cardiomyopathy	0.000605	0.00135	CcSEcCtD
Alitretinoin—Vomiting—Furosemide—dilated cardiomyopathy	0.0006	0.00134	CcSEcCtD
Alitretinoin—Rash—Furosemide—dilated cardiomyopathy	0.000595	0.00133	CcSEcCtD
Alitretinoin—Dermatitis—Furosemide—dilated cardiomyopathy	0.000594	0.00132	CcSEcCtD
Alitretinoin—Headache—Furosemide—dilated cardiomyopathy	0.000591	0.00132	CcSEcCtD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000586	0.00186	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000586	0.00186	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—NR3C2—dilated cardiomyopathy	0.000585	0.00186	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—NR3C2—dilated cardiomyopathy	0.000585	0.00186	CbGpPWpGaD
Alitretinoin—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000583	0.0013	CcSEcCtD
Alitretinoin—RXRA—PPARA activates gene expression—AGT—dilated cardiomyopathy	0.000579	0.00184	CbGpPWpGaD
Alitretinoin—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000579	0.00129	CcSEcCtD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.00057	0.00182	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.00057	0.00182	CbGpPWpGaD
Alitretinoin—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—dilated cardiomyopathy	0.000567	0.0018	CbGpPWpGaD
Alitretinoin—RXRA—a6b1 and a6b4 Integrin signaling—EGFR—dilated cardiomyopathy	0.000563	0.00179	CbGpPWpGaD
Alitretinoin—Urticaria—Lisinopril—dilated cardiomyopathy	0.000562	0.00125	CcSEcCtD
Alitretinoin—Nausea—Furosemide—dilated cardiomyopathy	0.00056	0.00125	CcSEcCtD
Alitretinoin—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000559	0.00125	CcSEcCtD
Alitretinoin—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000559	0.00125	CcSEcCtD
Alitretinoin—RXRA—Adipogenesis—FAS—dilated cardiomyopathy	0.000541	0.00172	CbGpPWpGaD
Alitretinoin—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000521	0.00116	CcSEcCtD
Alitretinoin—RXRA—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00052	0.00166	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000517	0.00165	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000514	0.00164	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000514	0.00164	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000509	0.00162	CbGpPWpGaD
Alitretinoin—Asthenia—Lisinopril—dilated cardiomyopathy	0.000508	0.00113	CcSEcCtD
Alitretinoin—RXRA—Adipogenesis—AGT—dilated cardiomyopathy	0.000506	0.00161	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000506	0.00161	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000506	0.00161	CbGpPWpGaD
Alitretinoin—Pruritus—Lisinopril—dilated cardiomyopathy	0.000501	0.00112	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000496	0.00158	CbGpPWpGaD
Alitretinoin—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000484	0.00108	CcSEcCtD
Alitretinoin—RXRA—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00047	0.0015	CbGpPWpGaD
Alitretinoin—RXRG—Adipogenesis—TNF—dilated cardiomyopathy	0.000468	0.00149	CbGpPWpGaD
Alitretinoin—Dizziness—Lisinopril—dilated cardiomyopathy	0.000468	0.00104	CcSEcCtD
Alitretinoin—Vomiting—Lisinopril—dilated cardiomyopathy	0.00045	0.001	CcSEcCtD
Alitretinoin—Rash—Lisinopril—dilated cardiomyopathy	0.000446	0.000995	CcSEcCtD
Alitretinoin—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000446	0.000994	CcSEcCtD
Alitretinoin—Headache—Lisinopril—dilated cardiomyopathy	0.000443	0.000988	CcSEcCtD
Alitretinoin—RARA—Adipogenesis—TNF—dilated cardiomyopathy	0.00044	0.0014	CbGpPWpGaD
Alitretinoin—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	0.000434	0.00138	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000428	0.00136	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—NPPA—dilated cardiomyopathy	0.000427	0.00136	CbGpPWpGaD
Alitretinoin—Nausea—Lisinopril—dilated cardiomyopathy	0.00042	0.000937	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000412	0.00131	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000412	0.00131	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	0.000397	0.00127	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000397	0.00127	CbGpPWpGaD
Alitretinoin—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000396	0.00126	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—NPPA—dilated cardiomyopathy	0.000391	0.00124	CbGpPWpGaD
Alitretinoin—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	0.00039	0.00124	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.00039	0.00124	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—NPPA—dilated cardiomyopathy	0.000383	0.00122	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—NPPA—dilated cardiomyopathy	0.000367	0.00117	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—NPPA—dilated cardiomyopathy	0.000367	0.00117	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000362	0.00115	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.000359	0.00114	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000355	0.00113	CbGpPWpGaD
Alitretinoin—RXRA—Transcriptional regulation of white adipocyte differentiation—TNF—dilated cardiomyopathy	0.000349	0.00111	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—ANKRD1—dilated cardiomyopathy	0.000342	0.00109	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.00034	0.00108	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000338	0.00108	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000334	0.00106	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000324	0.00103	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000322	0.00102	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—TAZ—dilated cardiomyopathy	0.000321	0.00102	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—NR3C2—dilated cardiomyopathy	0.000305	0.00097	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—SDHA—dilated cardiomyopathy	0.000291	0.000926	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—GPX1—dilated cardiomyopathy	0.000261	0.000831	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—GPX1—dilated cardiomyopathy	0.000261	0.000831	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000258	0.000823	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000257	0.00082	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—CD36—dilated cardiomyopathy	0.000254	0.000809	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—CD36—dilated cardiomyopathy	0.000254	0.000809	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000245	0.00078	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.00023	0.000733	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—TNF—dilated cardiomyopathy	0.00023	0.000731	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—AGT—dilated cardiomyopathy	0.000229	0.000728	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—AGT—dilated cardiomyopathy	0.000229	0.000728	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000227	0.000722	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000208	0.000662	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000202	0.000644	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000202	0.000644	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—CD36—dilated cardiomyopathy	0.000193	0.000616	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—NPPA—dilated cardiomyopathy	0.000191	0.000609	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000188	0.000598	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—RAC1—dilated cardiomyopathy	0.000182	0.00058	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000177	0.000565	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000177	0.000564	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000177	0.000562	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000177	0.000562	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000173	0.00055	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000169	0.000537	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000168	0.000535	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000168	0.000535	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000165	0.000525	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000159	0.000506	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000156	0.000496	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000155	0.000495	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	0.000137	0.000435	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000137	0.000435	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	0.000128	0.000409	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—RAF1—dilated cardiomyopathy	0.000121	0.000385	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	0.000116	0.00037	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000109	0.000347	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000103	0.000329	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000103	0.000327	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	0.000103	0.000326	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	9.27e-05	0.000295	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—EGFR—dilated cardiomyopathy	8.28e-05	0.000264	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—GPX1—dilated cardiomyopathy	7.9e-05	0.000251	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—TNF—dilated cardiomyopathy	7.89e-05	0.000251	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CD36—dilated cardiomyopathy	7.69e-05	0.000245	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	7.08e-05	0.000225	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—AGT—dilated cardiomyopathy	6.92e-05	0.00022	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	6.74e-05	0.000215	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	5.66e-05	0.00018	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	5.51e-05	0.000175	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	4.96e-05	0.000158	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	4.1e-05	0.000131	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	3.16e-05	0.0001	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CD36—dilated cardiomyopathy	3.07e-05	9.79e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—AGT—dilated cardiomyopathy	2.77e-05	8.81e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	2.52e-05	8.02e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	2.45e-05	7.81e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	2.21e-05	7.03e-05	CbGpPWpGaD
